Indefinite Delivery Contract SPE2DX15D9103

This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $4,999,999, enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables. The contract covers various product categories such as injections, tablets, creams, auto-injectors, and specialty medications to support the recurring medical supply needs of military healthcare facilities and veterans' medical centers nationwide. With a period of performance through December 2025, this IDC positions DMS Pharmaceutical Group as a crucial supplier in the federal pharmaceutical supply chain, providing direct distribution of prescription drugs and pharmacy services to Department of Defense healthcare sites.

The task orders issued under this IDC reflect the diverse pharmaceutical requirements of the DLA, with delivery orders for specialized medications such as Xolair, Trikafta, Keytruda, Botox, Nucala, and other prescription drugs and medical supplies. The firm fixed-price delivery orders, ranging from hundreds to tens of thousands of dollars, are awarded without any set-aside designations, allowing DMS Pharmaceutical Group to leverage its status as a woman-owned small business to secure direct federal awards across multiple product categories and medical domains.